文献速递膀胱癌与上尿路尿路上皮癌

不同T1亚分期系统对非肌层浸润性膀胱癌复发与进展的预后作用:系统综述与荟萃分析

Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2025-11-14

黏膜肌层侵犯与进展相关(HR 2.65,95%CI 1.79-3.92,p<0.001),但与复发无关;微米亚分期(T1m/T1e,0.5 mm cutoff)与复发和进展均相关。

要点

  • 黏膜肌层侵犯与进展相关,但与复发无关。
  • 微米亚分期(0.5 mm cutoff)与复发和进展均相关。
  • 同一人群比较中,T1a vs T1b/c及T1m vs T1e的风险比支持亚分期分层价值。

核心结论

  • 组织解剖学亚分期与进展显著相关,但与复发无关。
  • 微米亚分期与复发和进展均相关,可能改善患者分层。
  • Rete Oncologica Lombarda亚分期在患者分层中显示一定前景。
  • 结果可能支持就最佳T1亚分期系统达成全球病理共识。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed/Medline、Embase、Scopus和Web of Science截至2025年1月发表的报告。
  • 遵循PRISMA指南,主要结局为疾病复发和进展。
  • 亚组分析在同一人群内评估组织解剖学和微米亚分期。

主要发现

  • 黏膜肌层侵犯与进展相关(HR 2.65,95%CI 1.79-3.92,p<0.001),与复发无关(HR 1.19,95%CI 0.88-1.61,p=0.3)。
  • 微米亚分期(T1m/T1e,0.5 mm cutoff)与复发相关(HR 2.01,95%CI 1.53-2.64,p<0.001)。
  • 微米亚分期(T1m/T1e,0.5 mm cutoff)与进展相关(HR 3.33,95%CI 2.47-4.49,p<0.001)。
  • 同一人群中T1a vs T1b/c的合并风险比(RR)为0.60(95%CI 0.45-0.80,p<0.001)。
  • 同一人群中T1m vs T1e的RR为0.39(95%CI 0.29-0.52,p<0.001)。

关键数值与推荐

  • 黏膜肌层侵犯进展HR 2.65(95%CI 1.79-3.92,p<0.001)。
  • 微米亚分期复发HR 2.01(95%CI 1.53-2.64,p<0.001)。
  • 微米亚分期进展HR 3.33(95%CI 2.47-4.49,p<0.001)。
  • T1a vs T1b/c的RR 0.60(95%CI 0.45-0.80,p<0.001)。
  • T1m vs T1e的RR 0.39(95%CI 0.29-0.52,p<0.001)。

临床怎么用

  • 组织解剖学亚分期可用于识别进展风险较高的T1患者,但不用于预测复发。
  • 微米亚分期(0.5 mm cutoff)可同时辅助评估复发和进展风险,优化患者分层。
  • Rete Oncologica Lombarda亚分期在分层中显示前景,可考虑进一步验证。
  • 结果支持推动全球病理共识以规范T1亚分期系统选择。

局限性

  • 主要局限性为术后管理存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Different substaging methods have been proposed for risk stratification of T1 non-muscle-invasive bladder cancer; however, no consensus exists. This systematic review and meta-analysis evaluates the prognostic value of various T1 substaging systems. METHODS: A systematic literature search was conducted using the PubMed/Medline, Embase, Scopus, and Web of Science databases to identify reports published until January 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The primary outcomes were disease recurrence and progression. A subgroup analysis evaluated histoanatomical and micrometric substaging within the same population. KEY FINDINGS AND LIMITATIONS: Fifty-seven studies met the inclusion criteria. Muscularis mucosae invasion was associated with progression (hazard ratio [HR]: 2.65, 95% confidence interval [CI]: 1.79-3.92, p < 0.001) but not with recurrence (HR: 1.19, 95% CI: 0.88-1.61, p = 0.3). Micrometric substaging (T1m/T1e, 0.5 mm cutoff) correlated with both recurrence (HR: 2.01, 95% CI: 1.53-2.64, p < 0.001) and progression (HR: 3.33, 95% CI: 2.47-4.49, p < 0.001). Considering the substaging systems applied to the same population, the pooled risk ratio (RR) for T1a versus T1b/c was 0.60 (95% CI: 0.45-0.80, p < 0.001), while the RR for T1m versus T1e was 0.39 (95% CI: 0.29-0.52, p < 0.001). The main limitation was heterogeneity in postsurgery management. CONCLUSIONS AND CLINICAL IMPLICATIONS: Histoanatomical substaging significantly associate with progression but not with recurrence. Micrometric substaging demonstrated an association with both recurrence and progression, potentially enhancing patient stratification. Rete Oncologica Lombarda substaging shows some promising results in stratifying patients. These results may support a global pathological consensus on the optimal T1 substaging system.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Piccolini A, Moretto S, Fasulo V, et al. Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2025. PMID: 41241655. doi:10.1016/j.euo.2025.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。